First outbreak of VIM-2 metallo-β-lactamase-producing in The Netherlands: microbiology, epidemiology and clinical outcomes
This study was designed to investigate the prevalence and characteristics of metallo-β-lactamase (MBL)-producing in a tertiary care centre in The Netherlands, a country that is considered to have a low prevalence of antibiotic-resistant bacteria. Imipenem-resistant isolates cultured from clinical sp...
Gespeichert in:
Veröffentlicht in: | International journal of antimicrobial agents 2011-04 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | International journal of antimicrobial agents |
container_volume | |
creator | van Der Bij, A.K. van Mansfeld, R. Peirano, G. Goessens, W.H.F. Severin, J.A. Pitout, J.D.D. Willems, R. van Westreenen, M. |
description | This study was designed to investigate the prevalence and characteristics of metallo-β-lactamase (MBL)-producing in a tertiary care centre in The Netherlands, a country that is considered to have a low prevalence of antibiotic-resistant bacteria. Imipenem-resistant isolates cultured from clinical specimens during 2008-2009 were analysed phenotypically and molecularly by polymerase chain reaction (PCR) with sequencing. Genotyping was performed by multiple-locus variable-number tandem repeat (VNTR) analysis (MLVA). Clinical information was obtained by electronic chart review for all patients infected or colonised with an imipenem-resistant isolate that was included in the study. In total, 106 imipenem-resistant isolates were included. The gene was detected in 35/106 isolates (33%) and was associated with integrons. Compared with non-MBL-producing imipenem-resistant , VIM-2 MBL-producing isolates showed higher rates of multidrug resistance. Patients with VIM-2 MBL-producing isolates were more likely to be admitted to the Intensive Care Unit (ICU) and had a higher risk of invasive infection, including development of bacteraemia. MLVA identified two separate VIM-2 MBL-producing clones, responsible for outbreaks in the ICU but also affecting 10 other departments. This is the first reported outbreak of VIM-2 MBL-producing in The Netherlands. Once introduced, VIM-2 MBL-producing cause significant infections and are easily spread within the hospital setting. |
doi_str_mv | 10.1016/j.ijantimicag.2011.02.010 |
format | Article |
fullrecord | <record><control><sourceid>hal</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_00690061v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_HAL_hal_00690061v1</sourcerecordid><originalsourceid>FETCH-hal_primary_oai_HAL_hal_00690061v13</originalsourceid><addsrcrecordid>eNqVjk1OwzAUhL0AifJzh8cSCYfntCmEHUJURQJWFdvo1XGTF-w4sl2kiltxEM7UVHABFqPRjD5pRohLhZlCNb_pMu6oT-xYU5PlqFSGeYYKj8QEy3wm74rb8kScxtghqmI6Kybia8EhJvDbtA6GPsBv4P35VebgTCJrvfz5lpZ0IkfRyCH4equ5b4B7WLUG3kxqTbDU1_Eext3g1-ytb3bXYAaujftNMAKgLffjM3sY096ZeC6ON2SjufjzM3G1eFo9LmVLthoCOwq7yhNXy4eX6tAhzstR6lNN_8PuAZzcW8k</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>First outbreak of VIM-2 metallo-β-lactamase-producing in The Netherlands: microbiology, epidemiology and clinical outcomes</title><source>Elsevier ScienceDirect Journals</source><creator>van Der Bij, A.K. ; van Mansfeld, R. ; Peirano, G. ; Goessens, W.H.F. ; Severin, J.A. ; Pitout, J.D.D. ; Willems, R. ; van Westreenen, M.</creator><creatorcontrib>van Der Bij, A.K. ; van Mansfeld, R. ; Peirano, G. ; Goessens, W.H.F. ; Severin, J.A. ; Pitout, J.D.D. ; Willems, R. ; van Westreenen, M.</creatorcontrib><description>This study was designed to investigate the prevalence and characteristics of metallo-β-lactamase (MBL)-producing in a tertiary care centre in The Netherlands, a country that is considered to have a low prevalence of antibiotic-resistant bacteria. Imipenem-resistant isolates cultured from clinical specimens during 2008-2009 were analysed phenotypically and molecularly by polymerase chain reaction (PCR) with sequencing. Genotyping was performed by multiple-locus variable-number tandem repeat (VNTR) analysis (MLVA). Clinical information was obtained by electronic chart review for all patients infected or colonised with an imipenem-resistant isolate that was included in the study. In total, 106 imipenem-resistant isolates were included. The gene was detected in 35/106 isolates (33%) and was associated with integrons. Compared with non-MBL-producing imipenem-resistant , VIM-2 MBL-producing isolates showed higher rates of multidrug resistance. Patients with VIM-2 MBL-producing isolates were more likely to be admitted to the Intensive Care Unit (ICU) and had a higher risk of invasive infection, including development of bacteraemia. MLVA identified two separate VIM-2 MBL-producing clones, responsible for outbreaks in the ICU but also affecting 10 other departments. This is the first reported outbreak of VIM-2 MBL-producing in The Netherlands. Once introduced, VIM-2 MBL-producing cause significant infections and are easily spread within the hospital setting.</description><identifier>ISSN: 0924-8579</identifier><identifier>DOI: 10.1016/j.ijantimicag.2011.02.010</identifier><language>eng</language><publisher>Elsevier</publisher><subject>Life Sciences ; Microbiology and Parasitology</subject><ispartof>International journal of antimicrobial agents, 2011-04</ispartof><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://hal.science/hal-00690061$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>van Der Bij, A.K.</creatorcontrib><creatorcontrib>van Mansfeld, R.</creatorcontrib><creatorcontrib>Peirano, G.</creatorcontrib><creatorcontrib>Goessens, W.H.F.</creatorcontrib><creatorcontrib>Severin, J.A.</creatorcontrib><creatorcontrib>Pitout, J.D.D.</creatorcontrib><creatorcontrib>Willems, R.</creatorcontrib><creatorcontrib>van Westreenen, M.</creatorcontrib><title>First outbreak of VIM-2 metallo-β-lactamase-producing in The Netherlands: microbiology, epidemiology and clinical outcomes</title><title>International journal of antimicrobial agents</title><description>This study was designed to investigate the prevalence and characteristics of metallo-β-lactamase (MBL)-producing in a tertiary care centre in The Netherlands, a country that is considered to have a low prevalence of antibiotic-resistant bacteria. Imipenem-resistant isolates cultured from clinical specimens during 2008-2009 were analysed phenotypically and molecularly by polymerase chain reaction (PCR) with sequencing. Genotyping was performed by multiple-locus variable-number tandem repeat (VNTR) analysis (MLVA). Clinical information was obtained by electronic chart review for all patients infected or colonised with an imipenem-resistant isolate that was included in the study. In total, 106 imipenem-resistant isolates were included. The gene was detected in 35/106 isolates (33%) and was associated with integrons. Compared with non-MBL-producing imipenem-resistant , VIM-2 MBL-producing isolates showed higher rates of multidrug resistance. Patients with VIM-2 MBL-producing isolates were more likely to be admitted to the Intensive Care Unit (ICU) and had a higher risk of invasive infection, including development of bacteraemia. MLVA identified two separate VIM-2 MBL-producing clones, responsible for outbreaks in the ICU but also affecting 10 other departments. This is the first reported outbreak of VIM-2 MBL-producing in The Netherlands. Once introduced, VIM-2 MBL-producing cause significant infections and are easily spread within the hospital setting.</description><subject>Life Sciences</subject><subject>Microbiology and Parasitology</subject><issn>0924-8579</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqVjk1OwzAUhL0AifJzh8cSCYfntCmEHUJURQJWFdvo1XGTF-w4sl2kiltxEM7UVHABFqPRjD5pRohLhZlCNb_pMu6oT-xYU5PlqFSGeYYKj8QEy3wm74rb8kScxtghqmI6Kybia8EhJvDbtA6GPsBv4P35VebgTCJrvfz5lpZ0IkfRyCH4equ5b4B7WLUG3kxqTbDU1_Eext3g1-ytb3bXYAaujftNMAKgLffjM3sY096ZeC6ON2SjufjzM3G1eFo9LmVLthoCOwq7yhNXy4eX6tAhzstR6lNN_8PuAZzcW8k</recordid><startdate>20110421</startdate><enddate>20110421</enddate><creator>van Der Bij, A.K.</creator><creator>van Mansfeld, R.</creator><creator>Peirano, G.</creator><creator>Goessens, W.H.F.</creator><creator>Severin, J.A.</creator><creator>Pitout, J.D.D.</creator><creator>Willems, R.</creator><creator>van Westreenen, M.</creator><general>Elsevier</general><scope>1XC</scope><scope>VOOES</scope></search><sort><creationdate>20110421</creationdate><title>First outbreak of VIM-2 metallo-β-lactamase-producing in The Netherlands: microbiology, epidemiology and clinical outcomes</title><author>van Der Bij, A.K. ; van Mansfeld, R. ; Peirano, G. ; Goessens, W.H.F. ; Severin, J.A. ; Pitout, J.D.D. ; Willems, R. ; van Westreenen, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-hal_primary_oai_HAL_hal_00690061v13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Life Sciences</topic><topic>Microbiology and Parasitology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Der Bij, A.K.</creatorcontrib><creatorcontrib>van Mansfeld, R.</creatorcontrib><creatorcontrib>Peirano, G.</creatorcontrib><creatorcontrib>Goessens, W.H.F.</creatorcontrib><creatorcontrib>Severin, J.A.</creatorcontrib><creatorcontrib>Pitout, J.D.D.</creatorcontrib><creatorcontrib>Willems, R.</creatorcontrib><creatorcontrib>van Westreenen, M.</creatorcontrib><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>International journal of antimicrobial agents</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Der Bij, A.K.</au><au>van Mansfeld, R.</au><au>Peirano, G.</au><au>Goessens, W.H.F.</au><au>Severin, J.A.</au><au>Pitout, J.D.D.</au><au>Willems, R.</au><au>van Westreenen, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>First outbreak of VIM-2 metallo-β-lactamase-producing in The Netherlands: microbiology, epidemiology and clinical outcomes</atitle><jtitle>International journal of antimicrobial agents</jtitle><date>2011-04-21</date><risdate>2011</risdate><issn>0924-8579</issn><abstract>This study was designed to investigate the prevalence and characteristics of metallo-β-lactamase (MBL)-producing in a tertiary care centre in The Netherlands, a country that is considered to have a low prevalence of antibiotic-resistant bacteria. Imipenem-resistant isolates cultured from clinical specimens during 2008-2009 were analysed phenotypically and molecularly by polymerase chain reaction (PCR) with sequencing. Genotyping was performed by multiple-locus variable-number tandem repeat (VNTR) analysis (MLVA). Clinical information was obtained by electronic chart review for all patients infected or colonised with an imipenem-resistant isolate that was included in the study. In total, 106 imipenem-resistant isolates were included. The gene was detected in 35/106 isolates (33%) and was associated with integrons. Compared with non-MBL-producing imipenem-resistant , VIM-2 MBL-producing isolates showed higher rates of multidrug resistance. Patients with VIM-2 MBL-producing isolates were more likely to be admitted to the Intensive Care Unit (ICU) and had a higher risk of invasive infection, including development of bacteraemia. MLVA identified two separate VIM-2 MBL-producing clones, responsible for outbreaks in the ICU but also affecting 10 other departments. This is the first reported outbreak of VIM-2 MBL-producing in The Netherlands. Once introduced, VIM-2 MBL-producing cause significant infections and are easily spread within the hospital setting.</abstract><pub>Elsevier</pub><doi>10.1016/j.ijantimicag.2011.02.010</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0924-8579 |
ispartof | International journal of antimicrobial agents, 2011-04 |
issn | 0924-8579 |
language | eng |
recordid | cdi_hal_primary_oai_HAL_hal_00690061v1 |
source | Elsevier ScienceDirect Journals |
subjects | Life Sciences Microbiology and Parasitology |
title | First outbreak of VIM-2 metallo-β-lactamase-producing in The Netherlands: microbiology, epidemiology and clinical outcomes |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T04%3A07%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-hal&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=First%20outbreak%20of%20VIM-2%20metallo-%CE%B2-lactamase-producing%20in%20The%20Netherlands:%20microbiology,%20epidemiology%20and%20clinical%20outcomes&rft.jtitle=International%20journal%20of%20antimicrobial%20agents&rft.au=van%20Der%20Bij,%20A.K.&rft.date=2011-04-21&rft.issn=0924-8579&rft_id=info:doi/10.1016/j.ijantimicag.2011.02.010&rft_dat=%3Chal%3Eoai_HAL_hal_00690061v1%3C/hal%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |